Clinical applications of zolmitriptan (Zomig™, 311C90)

R. B. Lipton; W. F. Stewart

doi:10.1177/0333102497017S1807

Clinical applications of zolmitriptan (Zomig™, 311C90)

R. B. Lipton, W. F. Stewart

Neurology

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Zolmitriptan (Zomig™, formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.

Original language	English (US)
Pages (from-to)	53-59
Number of pages	7
Journal	Cephalalgia
Volume	17
Issue number	18_suppl
DOIs	https://doi.org/10.1177/0333102497017S1807
State	Published - Oct 1 1997

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1177/0333102497017S1807

Cite this

@article{dbd6b00396cf46389e605931b1ef079c,

title = "Clinical applications of zolmitriptan (Zomig{\texttrademark}, 311C90)",

abstract = "Zolmitriptan (Zomig{\texttrademark}, formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.",

author = "Lipton, {R. B.} and Stewart, {W. F.}",

note = "Publisher Copyright: {\textcopyright} International Headache Society.",

year = "1997",

month = oct,

day = "1",

doi = "10.1177/0333102497017S1807",

language = "English (US)",

volume = "17",

pages = "53--59",

journal = "Cephalalgia",

issn = "0333-1024",

publisher = "SAGE Publications Ltd",

number = "18_suppl",

}

TY - JOUR

T1 - Clinical applications of zolmitriptan (Zomig™, 311C90)

AU - Lipton, R. B.

AU - Stewart, W. F.

N1 - Publisher Copyright: © International Headache Society.

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Zolmitriptan (Zomig™, formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.

AB - Zolmitriptan (Zomig™, formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=0030781088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030781088&partnerID=8YFLogxK

U2 - 10.1177/0333102497017S1807

DO - 10.1177/0333102497017S1807

M3 - Article

C2 - 9399017

AN - SCOPUS:0030781088

SN - 0333-1024

VL - 17

SP - 53

EP - 59

JO - Cephalalgia

JF - Cephalalgia

IS - 18_suppl

ER -

Clinical applications of zolmitriptan (Zomig™, 311C90)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this